New Troponin T Assay Allows Earlier Detection of Myocardial Injury

The assay will be used on cobas and Modular Analytics serum work areas, in the United Kingdom and Ireland.

Launched by Roche (Burgess Hill, UK), Elecsys TnT hs is a commercially available assay, which not only meets the precision requirements (<10% coefficient of variation at the 99th percentile of the reference range) set down in the American College of Cardiology/European Society of Cardiology (ACC/ESC) and National Academy of Clinical Biochemistry/Academy of the American Association for Clinical Chemistry (NACB/AACC) definition of myocardial infarction, but also demonstrates the best level of assay designation (= 95% measurable normal values below the 99th percentile).

In addition, in a recent comparative evaluation, Elecsys TnT hs displayed the highest sensitivity (95 %) and negative predictive value (99%) in the diagnosis of unstable angina at presentation. This sensitivity and precision make the Elecsys TnT hs assay a valuable and much needed tool for the early detection and exclusion of acute myocardial infarction (AMI).

The Elecsys TnT hs assay is further indicated for the risk stratification of patients presenting with acute coronary syndrome (particularly in the risk assessment of chronic renal failure patients), providing a valuable aid in the selection of patients who may require more intensive therapy and intervention.

The robustness of the Elecsys TnT hs assay against interfering factors ensures accuracy and consistency in patient follow-up, and the availability of a STAT (9 min) version for rapid results delivers rapid turnaround time for emergency samples.

The cardiac portfolio from Roche offers the combination of a rapid turnaround time Point-of-Care (POC) Troponin T test with a higher sensitivity Elecsys TnT laboratory test, thus enabling medical institutions to deliver consistent and reliable results across hospital departments to support clinicians in their diagnosis of AMI.

Related Links:
Roche